June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
|Articles|April 15, 2019
Glaucoma and genetics: What’s ready for prime time?
Janey L. Wiggs, MD, PhD, shares the key points from her presentation.
Advertisement
Janey L. Wiggs, MD, PhD, shares the key points from her presentation, "Glaucoma and Genetics: What’s Ready for Prime Time?" at the 23rd annual Glaucoma 360 meeting at the Palace Hotel in San Francisco on Feb. 2, 2019.
Advertisement
Related to this article
Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
A large real-world cohort study finds OSA is associated with elevated glaucoma risk, though whether positive airway pressure therapy itself plays a role remains unclear.
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves subcutaneous Enspryng for TED
2
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
3
OT Roundup: Optogenetics Nobel Prize, BRUNELLO, DRAGON, eye transplant
4
Introducing Noah Banoub: The medical student’s path from church pews to the retina clinic
5